08329.HK
Shenzhen Neptunus Interlong Bio-technique Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 0.10
−6.67%Year over year
Reported trailing growth
- Revenue
- +13.2%
- EBITDA
- +26.6%
- EBIT
- —
- EPS
- —
- Free cash flow
- +322.5%
- Operating cash flow
- +226.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -0.5%
- EBITDA
- -27.3%
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +44.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026